Healthcare IT News February 1, 2024
Further guidance is needed to protect patients from “sycophantic” genAI documentation outputs that influence medical decisions, and researchers are asking the FDA “to clarify its oversight before summarization becomes a part of routine patient care.”
Doctors and researchers from the University of Maryland School of Medicine, the UMD Institute for Health Computing and the VA Maryland Healthcare System are concerned that large language models summarizing clinical data could meet the U.S. Food and Drug Administration’s device-exemption criteria and could cause patient harm.
WHY IT MATTERS
Artificial intelligence that summarizes clinical notes, medications and other patient data without FDA oversight will soon reach patients, doctors and researchers said in a new viewpoint published Monday on the JAMA Network.
They analyzed FDA’s...
Today's Sponsors
Today's Sponsor